DAX24.082 +0,2%ESt505.403 +0,5%Top 10 Crypto14,67 +1,1%Dow42.099 -0,6%Nas19.101 -0,5%Bitcoin96.354 +0,5%Euro1,1294 ±-0,0%Öl65,08 +0,2%Gold3.309 +0,6%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 Tesla A1CX3T BYD A0M4W9 Lufthansa 823212 Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 D-Wave Quantum A3DSV9 Deutsche Telekom 555750 Infineon 623100 thyssenkrupp 750000 Deutsche Bank 514000 Volkswagen (VW) vz. 766403
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX positiv - Rekord im Blick -- Asiens Börsen letztlich freundlich -- NVIDIA übertrifft Erwartungen -- US-Gericht erklärt Trumps Zölle für rechtswidrig -- GSK, Bilfinger, Deutsche Telekom im Fokus
Top News
FTSE 100-Wert Haleon-Aktie: Mit dieser Dividende bereitet Haleon Aktionären eine Freude FTSE 100-Wert Haleon-Aktie: Mit dieser Dividende bereitet Haleon Aktionären eine Freude
Deutsche Telekom-Aktie dennoch tiefer: S&P hebt Rating-Ausblick der Deutschen Telekom auf positiv an Deutsche Telekom-Aktie dennoch tiefer: S&P hebt Rating-Ausblick der Deutschen Telekom auf positiv an
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Cadrenal Therapeutics Aktie

Handeln
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Bei einem anderen Broker handelnSmartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DTQ8

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS1276361086

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCVKD

Cadrenal Therapeutics Aktien News

DatumMeistgelesen
PR NewswireCadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
PR NewswireCADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
PR NewswireCADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
PR NewswireCadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility
PR NewswireCADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
PR NewswireCadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference
PR NewswireCadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients
PR NewswirePublished Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients
PR NewswireCadrenal Therapeutics to Present at Upcoming Investor Conferences
PR NewswireCadrenal Therapeutics Provides Second Quarter 2024 Corporate Update
PR NewswireCadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs
PR NewswireCadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024
PR NewswireCadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024
PR NewswireCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients
PR NewswireCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
PR NewswireCadrenal Therapeutics Provides First Quarter 2024 Corporate Update
PR NewswireCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024
PR NewswireCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Ar...
PR NewswireCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update
PR NewswireCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference
PR NewswireCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial
PR NewswireCadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions
PR NewswireCadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
PR NewswireCadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference
PR NewswireNoble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target
PR NewswireCadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization
PR NewswireCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023
PR NewswireCadrenal Therapeutics Provides Third Quarter 2023 Corporate Update
PR NewswireCadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference
PR NewswireCadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology Congress
PR NewswireCadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)
PR NewswireCadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
PR NewswireCadrenal Therapeutics Provides Second Quarter 2023 Corporate Update
PR NewswireCadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
PR NewswireCadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
PR NewswireCadrenal Therapeutics Announces Closing of $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules
PR NewswireCadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq Rules
PR NewswireCadrenal Therapeutics to Participate in the 2023 BIO International Convention in Boston
PR NewswireCadrenal Therapeutics Provides First Quarter 2023 Corporate Update
PR NewswireCadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor Conference
Wer­bung

Cadrenal Therapeutics News

Cadrenal Therapeutics News: auf dieser Seite finden Sie alle Cadrenal Therapeutics News und Nachrichten zur Cadrenal Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Cadrenal Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Cadrenal Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.